Posters
The influence of two different postoperative anti-inflammatory drugs on the posterior capsule opacification development
Poster Details
First Author: D.Todorovic SERBIA
Co Author(s): T. Sarenac Vulovic S. Sreckovic S. Jovanovic N. Petrovic M. Janicijevic Petrovic
Abstract Details
Purpose:
The most common postoperative complication of a successfully performed phacoemulsification is the development of posterior capsule opacification. It is caused by the proliferation and migration of the remaining residual epithelial cells. The objective of this study was to investigate the influence of two different postoperative administrated anti-inflammatory drugs on the development of posterior capsule opacification in six months follow-up period.
Setting:
Clinic of Ophthalmology, Clinical Center Kragujevac, Serbia
Methods:
Investigation included 60 patients, (60 eyes), equally divided into two groups. The first group included patients who used postoperatively non steroid anti-inflammatory drug (NSAID), while the second group had corticosteroid therapy. All the patients got monofocal hydrophobic intraocular lenses. Software program EPCO 2000 was used for the analysis of PCO. Statistical analysis was done by using IBM SPSS. Student’s t-test, Wilcoxon test and ANOVA were used for data analysis and p < 0.05 value was accepted as statistically significant. The patients were examined one, two, three and six months after the phacoemulsification.
Results:
In the first three postoperative months patients from NSAID group had mean PCO score 0.22 ± 0.02, which was statistically significant higher (p = 0.031) comparing to corticosteroid group. At the end of the investigation the corticosteroid group had better mean PCO score, but without statistical significance (p = 0.068) comparing with the first group.
Conclusions:
This study has revealed that NSAID and corticosteroid therapy have showed similar results in preventing postoperative inflammation and consecutive posterior capsule opacification development. This fact can be very useful in situations when corticosteroids must be used with great caution.
Financial Disclosure:
None
